Feverfew: Side Effects and Post-Feverfew Syndrome
Feverfew is, by the standards of things people take daily for months, a gentle herb. In the largest trial, side effects possibly related to treatment occurred in 8.4 percent of people on feverfew and 10.2 percent on placebo — that is, slightly less often on the active drug (Diener 2005). The Cochrane review of all six trials found only “mild and transient adverse events, most commonly gastrointestinal complaints and mouth ulcers,” and concluded that feverfew “is not associated with any major safety concerns” (Wider 2015).
That is the honest headline, and it belongs up front rather than buried under warnings. But short trials in selected patients do not capture everything, and feverfew has four specific issues that a generic “consult your doctor” paragraph would fail you on: the withdrawal reaction, daisy-family allergy, mouth ulcers from chewing the leaf, and its antiplatelet effect. This page covers all four properly, and what is known about each.
Table of Contents
- The Overall Safety Picture
- Post-Feverfew Syndrome
- Stopping Gradually and the Rebound Risk
- Mouth Ulcers and Oral Irritation
- Asteraceae Allergy and Cross-Reactivity
- Antiplatelet Effects, Anticoagulants and Surgery
- Digestive Side Effects
- Pregnancy, Breastfeeding and Fertility
- Who the Research Raises Concerns For
- Drug Interactions
- Warning Signs That Need Medical Attention
- Key Research Papers
- Connections
- Featured Videos
The Overall Safety Picture
What the trial evidence actually supports:
- Diener 2005 — 16 weeks of a CO2 extract at 6.25 mg three times daily in 215 patients in the safety analysis. Treatment-related adverse events: 8.4% on feverfew versus 10.2% on placebo, P = 0.654. No signal at all.
- Pfaffenrath 2002 — 147 patients across three doses, 12 weeks. 35% reported at least one adverse event, but the incidence in the active groups was similar to placebo and no dose-related effect was seen in any safety parameter, including at 18.75 mg three times daily — three times the dose later used in the confirmatory trial.
- Curry 2004 — a phase I dose-escalation trial in cancer patients taking feverfew tablets daily on a 28-day cycle. No significant toxicity, and a maximum tolerated dose was never reached up to 4 mg parthenolide per day.
- Murphy 1988 — a crossover trial: after a one-month placebo run-in, 72 volunteers took one capsule of dried feverfew leaf a day for four months and matching placebo for four months, in random order; 60 completed. “There were no serious side-effects.”
- Cochrane 2015 — across six trials and 561 patients, only mild and transient events, most commonly gastrointestinal complaints and mouth ulcers.
- Nelaturi 2025 — an updated meta-analysis of nine double-blind, placebo-controlled trials with 899 participants found that feverfew reduced migraine attack frequency (mean difference −1.11 attacks), with risks of selection and attrition bias limiting the overall quality of the evidence. Its abstract reports efficacy, not side effects.
The limits of that evidence matter too. The longest trials ran about nine months as crossovers, in which each person took feverfew for only about four months (Murphy 1988), and the largest parallel trial treated people for 16 weeks (Diener 2005), so there are essentially no data on multi-year use. Trials exclude pregnant women, children, and people with significant comorbidity. And trial populations use a defined product, whereas real-world users take whatever they bought — a category with documented 160-fold variation in parthenolide delivered (Nelson 2002). Absence of a signal in a 16-week trial of a controlled extract is genuinely reassuring; it is not the same as proof of long-term safety for every product.
Post-Feverfew Syndrome
This is the caution most likely to catch you out, because it happens when you stop, and nothing on a supplement label warns you about it.
What it is: a withdrawal-type cluster reported in people who have taken feverfew regularly for a long period and then stop abruptly. The described features are:
- Rebound headache — migraines returning, often more frequent or more severe than before feverfew was started. This is the dominant feature.
- Anxiety and nervousness
- Insomnia and poor sleep quality
- Fatigue and low energy
- Muscle and joint stiffness or aching, sometimes described as a general achiness
- Nausea in some accounts
Where it comes from. The evidence base is thinner than the confident name suggests, and honesty requires saying so. The primary observation is in the 1985 BMJ trial (Johnson 1985), where 17 people who had been eating fresh feverfew daily were randomised to capsules of freeze-dried feverfew or placebo. Those switched to placebo — i.e. abruptly withdrawn from feverfew without knowing it — had a significant increase in the frequency and severity of headache, nausea and vomiting, “with the emergence of untoward effects during the early months of treatment.” Those untoward effects are the origin of the syndrome. The term “post-feverfew syndrome” itself entered the herbal and review literature from that observation and from subsequent user reports, and it is repeated in review articles (Pareek 2011) rather than resting on a dedicated study.
The review describes it in these words: people who switched to placebo “after taking feverfew for several years experienced a cluster of nervous system reactions (eg, headaches, insomnia, joint pain, nervousness, poor sleep patterns, stiffness, tension, tiredness) along with muscle and joint stiffness, often referred to as ‘postfeverfew’ syndrome” (Pareek 2011).
So the correct status is: a well-described clinical observation from a controlled trial, plus consistent user reports, without a dedicated withdrawal study. That explains why gradual stopping is commonly described, but it is not enough for incidence figures: no study has measured how often the syndrome occurs, so a quoted rate has no study behind it.
Why it might happen. Two plausible accounts, neither proven:
- Nerve resensitisation. In rodent studies (rat and mouse trigeminal nerve cells, and cells engineered to carry the channel), parthenolide acted on the TRPA1 channel of trigeminal nerve endings as a partial agonist that then desensitised them, leaving the pain fibres unresponsive — “defunctionalised” (Materazzi 2013). This has not been shown in people. Remove the compound and those terminals recover their sensitivity. A period of heightened reactivity as they come back online is exactly what you would predict, and it mirrors what happens when capsaicin treatment stops.
- Unmasking. If feverfew was genuinely suppressing attacks, stopping simply returns you to baseline — which feels much worse by contrast, and can be over-interpreted as a rebound. The 1985 trial cannot fully distinguish these, because the placebo group's deterioration is consistent with both.
Either way, the practical picture is the same: the reported problems are tied to stopping abruptly.
Stopping Gradually and the Rebound Risk
The withdrawal problems described above followed sudden stops. The 1985 trial’s placebo group was switched off feverfew abruptly; a review notes that “the abrupt discontinuation of feverfew caused incapacitating headaches in some patients” (Pareek 2011); and the US National Library of Medicine’s breastfeeding-medicines database (LactMed) states that “rebound headaches can occur with rapid discontinuation.” For that reason, reducing the dose gradually over a few weeks, rather than stopping at once, is the practice commonly described for people who have taken feverfew daily for more than a few weeks. No study has tested any particular taper schedule, and none of the sources on this page sets one out.
Three related points:
- Stopping because it did not help. After an abrupt stop, a rebound can be mistaken for proof that feverfew was working after all; a gradual stop gives a cleaner answer to that question.
- Surgery. The two-week pre-surgery stop often described for feverfew (see the bleeding section) concerns bleeding risk; a gradual reduction that is complete by then has to begin earlier.
- Rebound is not the same as medication-overuse headache. Acute painkillers taken on more than 10–15 days a month are a separate and very common cause of worsening headache, with its own treatment.
Mouth Ulcers and Oral Irritation
This is feverfew's signature adverse effect, and it is one of the two most commonly reported in the trial literature (Wider 2015).
What happens: painful aphthous-type ulcers inside the mouth, a sore or inflamed tongue and lips, swelling of the oral tissues, and sometimes a temporary loss or alteration of taste. It usually resolves within days to a couple of weeks after stopping.
A review reports that “in a larger series of feverfew users, 18% reported adverse effects, the most serious being mouth ulceration (11%),” and that feverfew “can induce more widespread inflammation of the oral mucosa and tongue, often with lip swelling and loss of taste” (Pareek 2011).
Who gets it: overwhelmingly people who chew fresh leaves, which is the traditional method. This makes chemical sense — parthenolide is a reactive electrophile that binds covalently to protein thiol groups, and pressing raw leaf against the mucosa delivers it at high local concentration to a delicate tissue.
What changes the risk:
- Capsules instead of fresh leaf. Dried-leaf or extract capsules swallowed whole bypass the oral mucosa almost entirely, which removes the main route of contact.
- Ulcers that appear on capsules are less expected and may indicate sensitivity.
- Persistent or recurrent mouth ulcers can also reflect iron, B12 or folate deficiency, coeliac disease, or other conditions, and blaming a supplement can delay finding the real cause. A mouth ulcer that has not healed in three weeks is one that doctors and dentists treat as needing examination.
Asteraceae Allergy and Cross-Reactivity
Feverfew belongs to the Asteraceae (Compositae) family — the daisy family, one of the largest plant families on earth. Family membership matters here because the sesquiterpene lactones that make these plants pharmacologically interesting also make them a leading cause of plant contact allergy in Europe.
Plants that commonly cross-react:
- Ragweed (Ambrosia) — the classic hay-fever cross-reactor
- Chrysanthemum and tansy
- Marigold (Calendula, Tagetes)
- Chamomile — both German and Roman; see Chamomile
- Daisies, yarrow, arnica, echinacea, artichoke, dandelion, lettuce, sunflower and many others
Feverfew is specifically recognised as “an important sensitizer in European Compositae-allergic patients, mainly because of its content of the sesquiterpene lactone parthenolide” (Paulsen 2010). That Danish study makes a further point worth knowing: when feverfew-allergic patients were patch tested with creams containing a parthenolide-depleted feverfew extract, four of seven still reacted — so removing the main sensitiser did not reliably make the extract safe for already-sensitised people. Occupational contact dermatitis to Tanacetum parthenium is also documented (Hashimoto 2019).
What reactions look like: most are contact reactions — itchy rash, redness, swelling where the plant touched skin, sometimes an airborne pattern on the face and neck in gardeners. Systemic allergic reactions to oral feverfew are rare but possible; lip, tongue or throat swelling, wheeze, or faintness are signs of a severe allergic reaction that hospitals treat as an emergency.
What this means in practice: the cross-reactivity data concern people with known ragweed, chrysanthemum, chamomile or general Compositae allergy. In that group the first signs of a reaction are rash, itching or swelling in the mouth; handling the fresh plant is the main route for contact reactions; and the gravest risk is for people who have had anaphylaxis to a plant in this family.
Antiplatelet Effects, Anticoagulants and Surgery
This caution is not theoretical hand-waving imported from a generic herb list — it comes directly from feverfew's own pharmacology, studied in human platelets.
Feverfew extracts inhibit platelet aggregation and the secretion of granules from platelets and white blood cells, blocking serotonin release triggered by ADP, adrenaline, arachidonate, collagen and thromboxane analogues (Heptinstall 1985). The mechanism appears to be neutralisation of sulphydryl groups on platelet proteins (Heptinstall 1987), and purified parthenolide reproduces the effect (Groenewegen 1990). Importantly, this works differently from aspirin — thromboxane synthesis is not inhibited — so the effects are not redundant and could in principle add together. A small 1982 study reported altered platelet aggregation responses in people actually taking feverfew for migraine (Biggs 1982).
What the platelet findings mean alongside other medicines:
- On warfarin: feverfew’s antiplatelet effect, shown in human platelets in the laboratory (Heptinstall 1985), may add to warfarin’s anticoagulant effect; warfarin’s effect is tracked with the international normalized ratio (INR) blood test.
- On a direct oral anticoagulant (DOAC) (apixaban, rivaroxaban, edoxaban, dabigatran): there is no international normalized ratio to watch with these drugs, so the bleeding signs listed at the end of this page are the main warning.
- On aspirin or clopidogrel: the combination is plausibly additive, because feverfew also inhibits platelet aggregation (Heptinstall 1985).
- With other antiplatelet supplements — high-dose fish oil, garlic, ginkgo, vitamin E, high-dose ginger, willow bark — the same logic applies, and stacking several is where problems become likely.
- Before surgery or dental extraction: the interval commonly described for stopping feverfew is about two weeks beforehand, tapered rather than abrupt because of the rebound risk. Platelet effects need time to wash out as new platelets circulate.
- With a bleeding disorder or low platelets: an added antiplatelet effect matters most in this group.
To keep this proportionate: no serious bleeding event attributable to feverfew appears in the trial literature, and the trials found no excess of adverse events overall. The concern is mechanistic and precautionary, and it is most relevant to people already on blood thinners or facing a procedure.
Digestive Side Effects
The other commonly reported category in trials. Nausea, indigestion, bloating, abdominal discomfort, wind and occasionally diarrhoea — generally mild and often settling within a couple of weeks.
Approaches described for reducing it: taking it with food; splitting the dose across the day rather than taking it all at once (the best trial dosed three times daily anyway); and starting at a lower dose and building up. Symptoms that persist past a few weeks suggest feverfew does not suit that person. Bitter herbs commonly cause this, and feverfew is notably bitter.
One longer-term theoretical concern has been raised in the review literature: feverfew has cyclooxygenase-2 (COX-2) inhibiting activity, and one systematic review flagged this as a reason for caution with very long-term dosing, particularly in people with coronary disease (Saranitzky 2009). In the review’s words, “there is some potential for concern with long-term dosing given its cyclooxygenase-2 inhibiting effects and longer-term studies will be needed to ameliorate these concerns in coronary disease patients.” No clinical harm has been demonstrated.
Pregnancy, Breastfeeding and Fertility
Pregnancy is the firmest caution on this page. Feverfew “is traditionally contraindicated in pregnancy but there are no studies confirming this warning” (Yao 2006); for a herb whose overall safety record is otherwise good, the concern rests on two independent reasons.
Traditional use. Feverfew has a long folk reputation as an emmenagogue — a substance used to bring on menstruation — and was historically given to assist labour and expel the placenta. Traditional use is not evidence of efficacy, but a plant traditionally used to affect the uterus is a plant whose uterine effects are the concern in pregnancy.
Experimental data. The only reproductive screening study is in rats, and its results do not reassure. Female rats were dosed orally with 839 mg/kg feverfew daily on gestation days 1–8 or 8–15. Fetuses exposed on days 8–15 were smaller than controls, apparently because of an increased frequency of runts in treated litters; pre-implantation loss appeared increased in the early-exposure group though not significantly; and feverfew induced toxicity in cultured rat embryos. The authors' conclusion was that a comprehensive reproductive study is warranted (Yao 2006).
Read that carefully: it is an animal screen at a high dose, and it is not evidence that feverfew causes birth defects in humans. What it is, is the only experimental look anyone has taken, and it came back with enough of a signal that the researchers asked for a full study — which has not been done. Set against a measured benefit of 0.6 attacks per month, that unresolved animal signal weighs heavily in pregnancy.
Breastfeeding: the US National Library of Medicine’s LactMed database states that “no data exist on the excretion of any components of feverfew into breastmilk or on the safety and efficacy of feverfew in nursing mothers or infants,” and that, because of the lack of safety data, “some reviewers recommend against its use during breastfeeding.” The same entry notes that rebound headaches can occur with rapid discontinuation.
Trying to conceive: organ formation (organogenesis) is well underway before most pregnancies are confirmed, and the rat data implicated the gestation day 8–15 window, so exposure in an early, not-yet-confirmed pregnancy is the relevant concern.
Who the Research Raises Concerns For
| Group | Why | Strength of the concern |
|---|---|---|
| Pregnant women | Emmenagogue tradition plus animal reproductive-toxicity signal | Firmest concern on this page |
| Breastfeeding women | No safety data | Some reviewers recommend against use (LactMed) |
| Known Asteraceae/Compositae allergy | Documented cross-reactivity; parthenolide is a recognised sensitiser | High; gravest after past anaphylaxis to this plant family |
| Children | Not adequately studied at any age | No safety data |
| People with bleeding disorders or low platelets | Antiplatelet activity | High |
| Anyone within two weeks of planned surgery | Bleeding risk | A tapered stop about two weeks before is commonly described |
| People on warfarin, direct oral anticoagulants, aspirin or clopidogrel | Additive antiplatelet effect | Plausible, not tested in trials |
| People who chew the fresh leaf | Mouth ulcers; uncontrolled dose; misidentification risk | Capsules avoid mouth contact |
| People with new, severe or changing headache | May signal another condition | Doctors treat such headaches as needing a diagnosis |
Drug Interactions
Feverfew has fewer documented interactions than its reputation suggests, and the ones that matter follow from its pharmacology rather than from case reports.
- Anticoagulants and antiplatelet drugs — the principal concern. Covered above.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) — theoretical additive effects on prostaglandin pathways and on gastric tolerance; also the cyclooxygenase-2 point raised by Saranitzky 2009, which matters most for regular users of nonsteroidal anti-inflammatory drugs.
- Triptans and other serotonergic drugs — often listed as a caution because feverfew affects platelet serotonin release. There is no clinical evidence of a serotonin-syndrome-type interaction, and the mechanism (blocking release from platelets) is not the mechanism of serotonin toxicity. Not a reason for alarm.
- Herbal blends — the practical risk is stacking several antiplatelet botanicals without realising it; the full ingredient list of a “migraine formula” shows whether it combines several.
- Cytochrome P450 — feverfew is not a well-established inducer or inhibitor of the major drug-metabolising enzymes, but it also has not been studied thoroughly. That gap matters most for narrow-therapeutic-index drugs — warfarin, digoxin, lithium, antiepileptics, immunosuppressants.
Warning Signs That Need Medical Attention
Signs that hospitals treat as urgent in someone taking feverfew:
- Swelling of the lips, tongue or throat, difficulty breathing, wheeze, or faintness — possible anaphylaxis
- Unusual bruising, bleeding gums, nosebleeds that will not stop, blood in urine or stool, or black tarry stools
- A sudden severe “worst ever” headache, headache with fever and neck stiffness, headache with new weakness, numbness, confusion, visual loss or speech difficulty, or headache after a head injury — these are emergency signs regardless of any supplement
Signs usually handled with a routine medical review are a persistent rash, mouth ulcers that do not settle after a switch to capsules, or digestive symptoms lasting beyond a few weeks. Jaundice (yellow skin or eyes) or dark urine are signs of liver injury that hospitals treat as urgent.
Supplements are omitted from medication lists constantly, and feverfew is one where the omission genuinely matters: before surgery or dental extraction, when an anticoagulant is started, and in pregnancy or when planning one.
Key Research Papers
Every identifier was verified live against NCBI E-utilities before being written here.
Withdrawal and overall tolerability
- Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. British Medical Journal (Clinical Research Ed.). 1985;291(6495):569–573 — PubMed PMID: 3929876 — The source of the post-feverfew withdrawal description: habitual users switched to placebo had significantly worse headache, nausea and vomiting with “untoward effects” in the early months.
- Wider B, Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database of Systematic Reviews. 2015;4(4):CD002286 — PubMed PMID: 25892430 — Only mild and transient adverse events across six trials; no major safety concerns.
- Diener HC, Pfaffenrath V, Schnitker J, Friede M, Henneicke-von Zepelin HH. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention. Cephalalgia. 2005;25(11):1031–1041 — PubMed PMID: 16232154 — Adverse events 8.4% versus 10.2% on placebo.
- Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. The Lancet. 1988;2(8604):189–192 — PubMed PMID: 2899663 — Crossover trial, four months of dried feverfew leaf and four of placebo per person; 72 randomised, 60 completed; “no serious side-effects.”
- Nelaturi V, Viswanatha GL, Shenoy RR, Khanna S, Krishnadas N. Systematic review and meta-analysis of Tanacetum parthenium: evaluating its efficacy in migraine relief. Natural Product Research. 2025:1–8 — PubMed PMID: 41422534 — Nine trials, 899 participants.
- Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis. Cephalalgia. 2002;22(7):523–532 — PubMed PMID: 12230594 — No dose-related effect on any safety parameter up to 18.75 mg three times daily.
- Curry EA 3rd, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs. 2004;22(3):299–305 — PubMed PMID: 15122077 — No dose-limiting toxicity; maximum tolerated dose not reached.
- Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): a systematic review. Pharmacognosy Reviews. 2011;5(9):103–110 — PubMed PMID: 22096324 — Review-level description of post-feverfew syndrome.
- Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutrition. 2000;3(4A):509–514. — PubMed PMID: 11276299
Allergy and contact sensitisation
- Paulsen E, Christensen LP, Fretté XC, Andersen KE. Patch test reactivity to feverfew-containing creams in feverfew-allergic patients. Contact Dermatitis. 2010;63(3):146–150 — PubMed PMID: 20690937 — Four of seven feverfew-allergic patients reacted to a parthenolide-depleted cream.
- Hashimoto T, Yokozeki H. Occupational contact dermatitis caused by Eucalyptus species and Tanacetum parthenium. Contact Dermatitis. 2019;80(5):333–334. — PubMed PMID: 30582184
- Sur R, Martin K, Liebel F, Lyte P, Shapiro S, Southall M. Anti-inflammatory activity of parthenolide-depleted feverfew (Tanacetum parthenium). Inflammopharmacology. 2009;17(1):42–49 — PubMed PMID: 19112586 — The extract developed specifically to remove parthenolide as a skin sensitiser.
Bleeding and platelet effects
- Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. The Lancet. 1985;1(8437):1071–1074. — PubMed PMID: 2860288
- Heptinstall S, Groenewegen WA, Spangenberg P, Lösche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. Journal of Pharmacy and Pharmacology. 1987;39(6):459–465. — PubMed PMID: 2886604
- Groenewegen WA, Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. Journal of Pharmacy and Pharmacology. 1990;42(8):553–557. — PubMed PMID: 1981582
- Biggs MJ, Johnson ES, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine. The Lancet. 1982;2(8301):776. — PubMed PMID: 6125851
- Saranitzky E, White CM, Baker EL, Baker WL, Coleman CI. Feverfew for migraine prophylaxis: a systematic review. Journal of Dietary Supplements. 2009;6(2):91–103 — PubMed PMID: 22435410 — Raises the long-term COX-2 inhibition question.
Pregnancy and mechanism of rebound
- Yao M, Ritchie HE, Brown-Woodman PD. A reproductive screening test of feverfew: is a full reproductive study warranted? Reproductive Toxicology. 2006;22(4):688–693 — PubMed PMID: 16781113 — The only experimental reproductive data; smaller fetuses and embryotoxicity in culture.
- Feverfew. In: Drugs and Lactation Database (LactMed). Bethesda (MD): National Institute of Child Health and Human Development; 2006– (entry revised 2022 Nov 30) — PubMed PMID: 30000921 — No data on transfer into breast milk; rebound headaches with rapid discontinuation.
- Materazzi S, Benemei S, Fusi C, et al. Parthenolide inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel. Pain. 2013;154(12):2750–2758 — PubMed PMID: 23933184 — Nerve defunctionalisation — the most plausible mechanism for a rebound on withdrawal.
- Nelson MH, Cobb SE, Shelton J. Variations in parthenolide content and daily dose of feverfew products. American Journal of Health-System Pharmacy. 2002;59(16):1527–1531 — PubMed PMID: 12185827 — Why trial safety data may not describe the product you bought.
PubMed Topic Searches
- PubMed: Feverfew adverse effects and safety
- PubMed: Post-feverfew syndrome and withdrawal
- PubMed: Compositae contact allergy
- PubMed: Parthenolide skin sensitisation
- PubMed: Herbal supplements and perioperative bleeding
- PubMed: Herbal medicine safety in pregnancy
- PubMed: Recurrent aphthous ulcers — other causes
- PubMed: Medication-overuse headache
Connections
- All Herbs
- Feverfew Benefits — hub
- Migraine Prevention — what the trials found
- How Parthenolide Works — the chemistry behind the side effects
- Choosing a Product and Dosing
- Feverfew — the main herb page
- Migraine
- Neurology
- Chamomile — the Asteraceae herb most likely to cross-react
- Butterbur — another Asteraceae migraine herb, with a liver-toxicity problem
- Ginger